Alivus Life Sciences
- Market cap
- ₹ 15,316 Cr.
- P/E
- 48.9x
- P/B
- 4.67x
- 52-week range
- 819 – 1,493.8
- ROE
- 18%
- ROCE
- 24%
- Dividend yield
- 0.4%
- Debt / equity
- 0.02
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Alivus Life Sciences Limited, formerly Glenmark Life Sciences Limited, is an India-based developer and manufacturer of non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas. The Company is providing contract development and manufacturing (CDMO) services to a range of multinational and specialty pharmaceutical companies. Its primary therapy areas include cardiovascular (CVS) disease, central nervous system (CNS) disorders, diabetes, oncology, pain management (anti-migraine, analgesic) and anti-infectives (antibiotic). It also develops APIs in the therapeutic areas such as antifungal, anti-histaminic, anti-acne, anti-emetic, ophthalmologic agent, urinary and anti-spasmodic. It has a diversified portfolio of around 151 molecules & supplies its products to customers in India, Europe, North America, Latin America, Japan and the rest of the world. Its four manufacturing facilities are located in Ankleshwar, Dahej, Mohol and Kurkumbh.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Alivus Life Sciences against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)48.9 against a typical 34.3: pricier than most peers (1st = cheapest).153rd of 220
- Sales growth+6.3% against a typical +15.6% from a year earlier.130th of 197
- Profit growth+31.1% against a typical +18.9% from a year earlier.68th of 160
- Share price, 3 months+24.5% against a typical −0.5%.28th of 200
- Size₹ 15,315.8 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).30th of 199
Latest announcements
Exchange filings and their impact on the company.
- Alivus paid Rs 14 cr for a 9.2% captive solar stake, a tiny ESG investment with negligible near-term earnings impact.
Alivus Life Sciences has acquired a 9.21% stake in Torrent Urja 19 Private Limited, a solar SPV, for Rs 14.04 crore in cash out of an approved up to Rs 16 crore. The SPV, incorporated in August 2024, has nil turnover and will supply renewable power for captive use to meet Electricity Act requirements. The outlay is very small versus Alivus's Rs 2,552 crore sales and supports its 2030 carbon-neutral target with only marginal power-cost savings expected in the next year.
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
High safety
Rated AA by India Ratings- No warnings from the agency.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| India Ratings | IND AA; IND A1+ | Stable | 16 Sep 2025 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 16 Sep 2025 | Rating action | IND AA | — | India Ratings | ₹ 700 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 29 Oct 2026Upcoming | Financial Results | Inter-alia to consider and approve the unaudited financial results for the quarter and half year ended September 30, 2026 |
| 30 Jul 2026 | Financial Results | To consider and approve the financial results for the period ended June 30, 2026 |
| 14 May 2026 | Financial Results/Dividend | To consider and approve the financial results for the quarter and year ended March 31, 2026 and to consider and recommend dividend, if any, on Equity Shares, for the year ended March 31, 2026. |
| 22 Jan 2026 | Financial Results | A meeting of the Board of Directors will be held on Thursday, January 22, 2026 inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter and nine months ended 31st December, 2025. |
| 6 Nov 2025 | Financial Results | To consider and approve the unaudited financial results for the quarter and half year ended September 30, 2025 |
| 1 Aug 2025 | Financial Results | inter alia, to consider and approve the financial results for the period ended Jun 30, 2025 |
| 15 May 2025 | Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2025 and dividend |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 595 | 573 | 537 | 589 | 507 | 642 | 650 | 602 | 588 | 673 | 689 | 640 |
| Expenses | 428 | 400 | 395 | 429 | 373 | 452 | 451 | 430 | 409 | 442 | 475 | 429 |
| Operating Profit | 167 | 173 | 141 | 159 | 134 | 190 | 198 | 172 | 179 | 231 | 215 | 212 |
| OPM % | 28% | 30% | 26% | 27% | 27% | 30% | 31% | 29% | 30% | 34% | 31% | 33% |
| Other Income | 5 | 2 | 3 | 5 | 9 | 10 | 10 | 9 | 15 | −12 | 23 | 22 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 13 | 13 | 15 | 14 | 15 | 15 | 16 | 17 | 18 | 20 | 20 | 21 |
| Profit before tax | 159 | 161 | 130 | 150 | 127 | 185 | 191 | 163 | 174 | 198 | 216 | 212 |
| Tax % | 25% | 26% | 24% | 26% | 25% | 26% | 26% | 25% | 25% | 24% | 25% | 25% |
| Net Profit | 119 | 119 | 98 | 111 | 95 | 137 | 142 | 122 | 130 | 150 | 163 | 160 |
| EPS in Rs | 9.69 | 9.69 | 7.99 | 9.1 | 7.78 | 11.18 | 11.58 | 9.91 | 10.6 | 12.25 | 13.25 | 13.04 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- 6%
- 3 Years
- 6%
- TTM
- 8%
- 10 Years
- —
- 5 Years
- 9%
- 3 Years
- 6%
- TTM
- 25%
- 10 Years
- —
- 5 Years
- 14%
- 3 Years
- 28%
- TTM
- —
- 10 Years
- —
- 5 Years
- 21%
- 3 Years
- 19%
- TTM
- —
P/E and EPS over time
Daily price to earnings ratio.
Peers
Listed companies in the same business.
| Alivus Life Sciences | ₹ 1,394.10 | ₹ 15,316 Cr. | 48.9x | 4.7x | 18% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Yasir Yusufali Rawjee
- Chief Executive Officer, Managing Director, Executive Director
- Tushar Mistry
- Chief Financial Officer, Senior Vice President
- Sumantra Mitra
- Senior Vice President - Human Resources, Head - Human Resources
- Navin Kumar Agrawal
- Senior Vice President - Quality, Head - Corporate Quality
- Mathew George
- Senior Vice President - Regulatory Affairs, Head - Regulatory Affairs
- Rudalf Joseph Corriea
- Company Secretary, Compliance Officer
- Palle V.R Acharyulu
- Group Vice President, Head - Research and Development
- Vinod Naik
- Head - Technical Operations, Whole Time Director
Prices are delayed and for information only. Nothing on this page is investment advice.